Minorities Lack Internet Access to Cancer Research Data

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 23 No 5
Volume 23
Issue 5

BETHESDA, Md--Cable television, not computers, may be the best way to reach the poor with information about cancer research, Harold P. Freeman, MD, said at a meeting of the National Cancer Advisory Board (NCAB) that focused on issues of minority recruitment into clinical trials.

BETHESDA, Md--Cable television, not computers, may be the bestway to reach the poor with information about cancer research,Harold P. Freeman, MD, said at a meeting of the National CancerAdvisory Board (NCAB) that focused on issues of minority recruitmentinto clinical trials.

Dr. Freeman, director of surgery, Harlem Hospital Center, andchair of the President's Cancer Panel, said that "we continueto isolate the poor, those without the equipment to search theInternet, those without phones to call for information. The Internethas elitist demographics, no quality control, and no securityof information."

He recommended that an "800" phone number be made availableand widely published for those without computers who want to obtainthe same information that is being given out on the Internet.And for those who have no telephones, Dr. Freeman said that cabletelevision is currently much used by the poor and by minoritycultures, and thus would be a good means of disseminating cancerinformation.

He added that, for those patients with Internet access, the balanceof power between patient and physician may shift. "In thefuture, patients will come to their physicians with more knowledge."

Recent Videos
Once a patient-specific dose is determined, an all-oral combination of revumenib plus decitabine/cedazuridine and venetoclax may be “very good” in AML.
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Related Content